Mar 03, 2020
Evolus to Participate in Barclays 2020 Global Healthcare Conference
|Event:||Barclays 2020 Global Healthcare Conference|
|Format:||Fireside chat & 1x1 Meetings|
An audio webcast of Evolus’ presentation will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.
Jeuveau® is a registered trademark of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Vice President, Finance, Investor Relations &